FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending October 15, 2008
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 


Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons


The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company
 and Mr Phelan on  14 October 2008 
of an increase in his
 interests in Ordinary
 share
ADRs at a price of $35.41
 per ADR following the re-investment of the dividend
 
paid to shareholders 
on 
9 October
 
2008
.


Mr D J Phelan
247.31




This notification relates to 
a 
transaction notified in accordance with
 
Disclosure 
and Transparency 
R
ule
 3.1.4R(1)(a)
.


S M Bicknell
Company Secretary

15 October
 
2008

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date:  October 15, 2008

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc